News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
307,845 Results
Type
Article (15328)
Company Profile (283)
Press Release (292234)
Section
Business (91495)
Career Advice (161)
Deals (16160)
Drug Delivery (35)
Drug Development (53647)
Employer Resources (31)
FDA (6847)
Job Trends (5533)
News (164982)
Policy (12310)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (955)
Accelerated approval (2)
Adcomms (12)
Allergies (53)
Alliances (26053)
ALS (61)
Alzheimer's disease (885)
Antibody-drug conjugate (ADC) (88)
Approvals (6877)
Artificial intelligence (115)
Autoimmune disease (13)
Automation (5)
Bankruptcy (110)
Best Places to Work (4797)
BIOSECURE Act (5)
Biosimilars (49)
Biotechnology (235)
Bladder cancer (47)
Brain cancer (19)
Breast cancer (153)
Cancer (1375)
Cardiovascular disease (113)
Career advice (140)
Career pathing (2)
CAR-T (107)
Cell therapy (313)
Cervical cancer (8)
Clinical research (43679)
Collaboration (526)
Compensation (226)
Complete response letters (13)
COVID-19 (1118)
CRISPR (37)
C-suite (152)
Cystic fibrosis (76)
Data (1420)
Denatured (11)
Depression (30)
Diabetes (131)
Diagnostics (1735)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (80)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (83)
Earnings (34082)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (52072)
Executive appointments (427)
FDA (7531)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (488)
Gene editing (89)
Generative AI (9)
Gene therapy (242)
GLP-1 (380)
Government (1195)
Grass and pollen (3)
Guidances (21)
Healthcare (7131)
Huntington's disease (21)
IgA nephropathy (22)
Immunology and inflammation (81)
Indications (19)
Infectious disease (1184)
Inflammatory bowel disease (115)
Inflation Reduction Act (8)
Influenza (23)
Intellectual property (64)
Interviews (17)
IPO (8096)
IRA (11)
Job creations (1038)
Job search strategy (135)
Kidney cancer (6)
Labor market (4)
Layoffs (207)
Leadership (2)
Legal (2134)
Liver cancer (39)
Lung cancer (197)
Lymphoma (88)
Machine learning (1)
Management (7)
Manufacturing (129)
MASH (52)
Medical device (3514)
Medtech (3516)
Mergers & acquisitions (8401)
Metabolic disorders (380)
Multiple sclerosis (54)
NASH (13)
Neurodegenerative disease (61)
Neuropsychiatric disorders (23)
Neuroscience (1266)
NextGen: Class of 2025 (2138)
Non-profit (891)
Northern California (1595)
Now hiring (21)
Obesity (192)
Opinion (100)
Ovarian cancer (60)
Pain (43)
Pancreatic cancer (56)
Parkinson's disease (109)
Partnered (9)
Patents (116)
Patient recruitment (67)
Peanut (35)
People (28070)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (15085)
Phase II (20131)
Phase III (13156)
Pipeline (771)
Podcasts (47)
Policy (38)
Postmarket research (991)
Preclinical (6295)
Press Release (32)
Prostate cancer (57)
Psychedelics (35)
Radiopharmaceuticals (220)
Rare diseases (281)
Real estate (1866)
Recruiting (12)
Regulatory (10072)
Reports (18)
Research institute (980)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (4)
RSV (10)
Schizophrenia (57)
Series A (94)
Series B (62)
Service/supplier (1)
Sickle cell disease (40)
Southern California (1422)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (2176)
State (1)
Stomach cancer (5)
Supply chain (19)
The Weekly (35)
United States (12645)
Vaccines (220)
Venture capitalists (29)
Webinars (7)
Weight loss (105)
Women's health (15)
Worklife (2)
Date
Today (90)
Last 7 days (488)
Last 30 days (1780)
Last 365 days (21208)
2025 (5117)
2024 (21855)
2023 (23967)
2022 (30247)
2021 (31137)
2020 (26588)
2019 (18342)
2018 (13442)
2017 (15635)
2016 (13739)
2015 (16811)
2014 (12452)
2013 (9312)
2012 (9526)
2011 (9706)
2010 (9313)
Location
Africa (195)
Alabama (38)
Alaska (2)
Arizona (59)
Arkansas (5)
Asia (30050)
Australia (4369)
California (3636)
Canada (1135)
China (372)
Colorado (138)
Connecticut (145)
Delaware (89)
Europe (44472)
Florida (425)
Georgia (111)
Idaho (16)
Illinois (219)
India (12)
Indiana (85)
Iowa (1)
Japan (114)
Kansas (63)
Kentucky (5)
Louisiana (3)
Maine (13)
Maryland (478)
Massachusetts (2908)
Michigan (70)
Minnesota (159)
Mississippi (1)
Missouri (25)
Montana (14)
Nebraska (4)
Nevada (16)
New Hampshire (14)
New Jersey (957)
New Mexico (12)
New York (1003)
North Carolina (538)
North Dakota (4)
Northern California (1595)
Ohio (108)
Oklahoma (9)
Oregon (22)
Pennsylvania (692)
Puerto Rico (3)
Rhode Island (15)
South America (273)
South Carolina (4)
Southern California (1422)
Tennessee (25)
Texas (414)
Utah (57)
Virginia (70)
Washington D.C. (29)
Washington State (323)
Wisconsin (17)
307,845 Results for "chemomab therapeutics ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
March 7, 2025
·
11 min read
Press Releases
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
March 3, 2025
·
16 min read
Press Releases
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 3, 2025
·
2 min read
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences - May 17, 2024
Chemomab Therapeutics Ltd. today announced upcoming scientific presentations at the Gordon Research Conference on Chemotactic Cytokines and at EASL 2024, the Annual Congress of the European Association for the Study of the Liver.
May 17, 2024
·
3 min read
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
Chemomab Therapeutics Ltd., a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the Aegis Virtual Conference on May 7, 2024 at 9:00 am ET. Dr. Mor’s presentation will be webcast live.
May 2, 2024
·
1 min read
Business
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, announced financial and operating results for the first quarter ended March 31, 2024, and provided a corporate update.
May 9, 2024
·
9 min read
Business
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics Ltd. announced the company will report its first quarter 2024 financial results and provide a business update on May 9, 2024, at 7:00 am Eastern Time.
April 24, 2024
·
1 min read
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
Chemomab Therapeutics Ltd. today announced a new scientific publication that further confirms the important role of the soluble protein CCL24 in the pathologies underlying the rare fibrotic liver disease primary sclerosing cholangitis (PSC).
June 18, 2024
·
6 min read
Chemomab Therapeutics to Participate in Upcoming February 2024 Investor Conferences
Chemomab Therapeutics Ltd. announced that CEO Dr. Adi Mor and other members of its senior management team will participate in two upcoming investor conferences.
February 5, 2024
·
2 min read
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
Chemomab Therapeutics Ltd., a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, announced that CEO Dr. Adi Mor will deliver a corporate presentation and participate in investor meetings at the Leerink Partners Global Biopharma Conference, March 11-13, 2024 in Miami, Florida.
March 5, 2024
·
1 min read
1 of 30,785
Next
